← Back to headlines
Palisade Bio's Lead IBD Drug Advances to Phase 2, Receives Bullish Call
Palisade Bio's leading drug candidate for Inflammatory Bowel Disease (IBD) is progressing towards Phase 2 trials, attracting a bullish assessment from analysts.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
